## Supplemental Table 2. Baseline Medication Use Administered or Prescribed Within 30 Days Prior to Index Date, by Cohort and Time Period

All Values are column	of medication usage with percentages, with blue sh							
		ratory Positive				Clinical Coho		
HARACTERISTIC	All (N = 37617)	y (n = 12978)	ag (n = 11416)	v (n = 13223) 1 All (F	N = 13893) <sup>↑↓</sup> Jan-M	ay (n = 7150) Ti June-A	ug (n = 3768) 1	ov (n = 297
ntiarrhythmics	1.2	1.06	1.04	1.47	1.86	1.85	1.86	
nticoagulants nticoagulants	10.9	9.81	10.29	12.51	13.47	12.83	13.88	
ntihyperlipidemics								
ntihyperlipidemics	25.55	27.08	22.94	26.3	24.57	24.42	24.02	
ntihypertensives Igiotensin-Receptor Blockers	9.18	9.35	8.86	9.29	8.08	7.52	8.63	
giotensin-Converting Enzyme Inhibitors	12.48	12.88	11.62	12.85	11.71	11.79	12.02	
alcium Channel Blockers	17.74	18.62 16.33	15.89 13.43	18.47	19.39	19.33 14.32	19.35	
azosin	0.23	0.15	0.31	0.24	0.4	0.39	0.5	
rect Renin Blocker ther Antihypertensives	0.01 4.34	0.01 4.78	4.28	0.01 3.95	0.01 4.94	0.01 4.85	4.64	
ntiplatelets	4.54	4.10	420	3.33	4.54	4.60	4.04	
ntiplatelets	18.14	18.65	16.14	19.35	18.74	17.66	19.21	
teplase	0.01	0.01	0.38	0.02	0.42	0.32	0.66	
vulizumab	0	0	0	0	0	0	0	
opidogrel ofiban	3.47	3.53	3.04	3.8	3.85	3.37	4.01	
oridamole	0.08	0.07	0.12	0.05	0.01	0.07	0.05	
ovin spirin	16.33	16.82	14.35	17.56	16.81	16	17.06	
spirin Low-Dose (<= 81 Mg)	14.91	15.59	13.12	15.79	15.28	14.63	15.34	
pirin High-Dose (> 81 Mg)	1.74	1.56	1.52	2.11	2.16	2.07	2.34	
er Antiplatelets	0.6	0.52	0.52	0.74	0.58	0.63	0.48	
etics	14.94	14.99	14.2	15.53	16.56	16.63	15.98	
cer Therapies								
cer Therapies nunomodulators	2.97	3.1	2.64	3.14	3.92	3.9	3.77	
munomodulators	1.02	1.07	0.98	0.99	1.29	1.37	1.33	
Inhibitors	0	0	0	0	0	0	0	
Inhibitors er Immunomodulators	0.02	0.01	0.01	0.03	0.01	0.01 1.36	0	
atopoletic Growth Factor								
matopoietic Growth Factor thropoiesis-Stimulating Agents	0.63	0.87	0.49	0.51	0.86	0.97	0.72	
thropolesis-Stimulating Agents er Hematopoletic Growth Factors	0.5	0.72	0.39	0.39	0.7	0.83	0.48	
osuppressive Chemotherapy	1.11	0.95	1.01	1.37	1.53	1.38	1.65	
h Or Intermediate Myelosuppressive	0.93	0.95	0.88	1.37	1.53	1.38	1.65	
ntial er Myelosuppressive Chemotherapies	0.25	0.24	0.14	0.36	0.32	0.34	0.27	
rer Myelosuppressive Chemotherapies er Antineoplastics	0.25	0.24	0.14	0.64	0.32	0.34	0.27	
diabetics	_							
diabetics	19.36 9.46	19.78 9.13	18.94 9.63	19.32 9.63	17.8 9.8	17.52 10.03	17.68 9.13	
lin Sensitizing Agents	9.46	9.13	9.63	9.63	9.8 8.57	10.03	9.13	
er Antidiabetics	7.93	7.91	7.56	8.27	6.73	6.28	7.27	
emic Steroids	10.00	74	10.4	14 ***	11.74	0.0	12	
esonide (Systemic)	10.92	7.41	10.45	14.77	11.74	9.92		
desonide (Systemic)	0.06	0.03	0.07	0.09	0.07	0.08	0.08	
desonide (Oral) desonide (Rectal)	0.06	0.03	0.07	0.09	0.07	0.08	0.08	
ocortisone (Systemic)								
drocortisone (Systemic) drocortisone (Oral)	0.14	0.12	0.13	0.15	0.18	0.17	0.11	
drocortisone (Rectal)	0.14	0.12	0.13	0.15	0.18	0.17	0.11	
drocortisone (Injection)	0.28	0.33	0.23	0.29	0.42	0.41	0.42	
ylprednisolone (Systemic) thylprednisolone (Systemic)	1.8	1.37	1.8	2.22	2.39	2.45	2.1	
thylprednisolone (Injection)	0.92	0.7	0.86	1.18	1.46	1.65	1.06	
thylprednisolone (Oral)	0.94	0.71	1.02	1.1	0.99	0.84	1.11	
imethasone (Systemic) xamethasone (Systemic)	4.22	1.33	4.16	7.12	3.4	1.78	3.77	
kamethasone (Injection)	1.14	0.87	1.24	1.32	1.3	1.16	1.27	
xamethasone (Oral) (nisone (Systemic)	3.14	0.5	3	5.84	2.14	0.63	2.47	
dnisone (Systemic)	4.74	3.98	4.42	5.76	6.23	6.24	6.08	
ednisone (Oral) er Systemic Steroids	4.74 0.45	3.98 0.37	4.42 0.45	0.54	6.23 0.45	6.24 0.34	6.08 0.45	
led Steroids	0.43	0.37	0.43	0.34	0.45	0.34	0.43	
led Steroids	5.99	6.22	5.05	6.58	6.69	6.94	6.32	
omethasone (Inhaled)	0.25	0.25	0.22	0.27	0.27	0.32 1.06	0.24	
sonide (Inhaled)	0.07	0.11	0.03	0.08	0.18	0.21	0.11	
casone (Inhaled)	5	5.24	4.15	5.5	5.48	5.59	5.25	
netasone (Inhaled) er Steroids	0.23 5.17	0.22 5.39	0.21 4.37	0.25 5.63	0.22 5.38	0.27 5.52	0.24 5.04	
er Steroids (Ophthalmic)	0.44	0.44	0.34	0.53	0.41	0.46	0.42	
er Steroids (Nasal)	4.79	5.04	4.05	5.17	5.05	5.17	4.67	
chodilators	16.66	16.62	15,05	18.08	20.35	19.86	20.22	
noterol	2.23	2.22	1.86	2.55	3.27	3.43	3.24	
telukast	2.84	2.69	2.61	3.18	3.25	2.97	3.34	
r Bronchodilators	15.28	15,58	13.74	16,33	19.11	18.85	18.71	
RDs	1.69	1.59	1.59	1.88	2.08	2.14	1.94	
phosphamide	0.04	0.05	0.02	0.05	0.1	0.14	0.03	
nomide	0.12	0.07	0.12	0.17	0.12	0.13	0.13	
otrexate	0.47	0.38	0.48	0.55	0.68	0.5	0.74	
salazine	0.12	0.11	0.09	0.16	0.11	0.1	0.16	
acept	0.01	0.02	0	0.01	0.01	0	0	
izumab	0.08	0.09	0.04	0.11	0.12	0.08	0.19	
mumab	0.09	0.11	0.09	0.08	0.14	0.15	0.13	
sinra	0	0	0	0	0	0	0	
milast olizumab Pegol	0.03	0.04	0.04	0.03	0.03	0.01	0.03	
olizumab Pegol ercept	0.02	0.01	0.01	0.03	0.05	0.04	0.08	
numab	0.01	0.02	0	0.01	0.01	0	0.03	
imab hioprine	0.05	0.02	0.04	0.08	0.06	0.06	0.05	
nioprine	0.14	0.08	0.16	0.17	0.14	0.1	0.16	
dacitinib	0.02	0.01	0	0.04	0	0	0	
skinumab	0	0	0	0	0	0	0	
acept	0	0.01	0	0	0	0	0	
ximab	0	0	0	0	0	0	0	
r DMARDs	0.26	0.24	0.24	0.29	0.22	0.21	0.19	
rirals	1.55	2.31	1.16	1.15	1.77	2.29	1.35	
ntivirals	0.37	0.55	0.39	0.2	0.48	0.66	0.37	
enza Antivirals	0.5	1.12	0.15	0.18	0.53	0.84	0.27	
r Antivirals gesics	0.71	0.7	0.64	0.79	0.86	0.95	0.8	
gesics	26.39	27.07	24.79	27.1	30.47	28.99	32.25	
minophen	18.44	19.84	17.06	18.25	21.62	21.41	21.82	
ilDs	8.41	7.94	8.51	8.78	9.37	8.49	10.32	
profen	3.75	3.93	3.63	3.68	4.43	3.93	5.12	
roxen	1.41	1.36	1.46	1.41	1.48	1.51	1.46	
omethacin er NSAIDs	0.2 3.83	0.17 3.21	0.23	0.22 4.3	0.19 4.35	0.25 3.87	0.08 4.75	
er NSAIDs ids	3.83	3.21 10.48	11.84	4.3 13.63	4.35 15.97	3.87 14.11	4.75 17.91	
r Analgesics	0.72	0.63	0.6	0.89	0.71	0.55	1.06	
psychotics								
sychotics Density Regulators	5.42	5.76	5.04	5,41	6.8	6.67	6.79	
Density Regulators	1.17	0.97	0.97	1.53	1.19	1.05	1.27	
osozumab	0.01	0	0.01	0.02	0.01	0	0	
osumab	0.2	0.14	0.14	0.32	0.17	0.14	0.24	
hosphonates				0.1	0.94	0.85	0.93	
	0.1	0.07	0.12				0.11	
er Bone Density Regulators	_							
er Bone Density Regulators on <b>Pump Inhibitors</b> on Pump Inhibitors	0.1 15.45	0.07 14.56	0.12	17.58	18.02	17.26	18.79	
hosphonates or Bone Density Regulators ton Pump Inhibitors on Pump Inhibitors Receptor Antagonists Receptor Antagonists	_							